Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis

OBJECTIVE: To evaluate the long-term safety and efficacy of adalimumab in patients with ankylosing spondylitis (AS) and total spinal ankylosis (TSA). DESIGN: Patients (n = 315) with active AS were randomised in a 2:1 ratio to receive adalimumab 40 mg every other week or placebo for 24 weeks followed...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: van der Heijde, D, Pangan, A L, Schiff, M H, Braun, J, Borofsky, M, Torre, J, Davis, J C, Wong, R L, Kupper, H, Collantes, E
Natura: Artigo
Lingua:Inglês
Pubblicazione: BMJ Publishing Group 2008
Soggetti:
Extended Reports
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC2564805/
https://ncbi.nlm.nih.gov/pubmed/18056755
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ard.2007.082529
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi